Entrada Therapeutics, Inc. (TRDA)

$19.04

+0.24

(+1.28%)

Market is closed - opens 8 PM, 26 Nov 2024

Entrada Therapeutics, Inc. Key Statistics

Market Capitalization
$703.5M
Revenue TTM
$215.2M
EBITDA
$61.3M
Earnings Per Share (EPS)
$1.44
PE Ratio
13.06
Profit Margin
25.53%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
16.42%

Entrada Therapeutics, Inc. share price movements

  • $19.04
    $19.71
    $19.04
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.4%

    Upside

    3.4%

    downward going graph
  • $11.05
    $20.49
    $19.04
    downward going graph

    41.96%

    Downside

    52 Weeks Volatility :46.07%

    Upside

    7.08%

    downward going graph

Entrada Therapeutics, Inc. Returns

PeriodEntrada Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
12.6%
-6.4%
0.0%
6 Months
17.97%
0.7%
0.0%
1 Year
52.32%
10.9%
0.0%
3 Years
-34.14%
10.2%
-21.2%

Analyst Recommendation on Entrada Therapeutics, Inc.

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Entrada Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast on Entrada Therapeutics, Inc.

What analysts predicted

Upside of 34.3%

Current $19.04
Target $25.57

Insights on Entrada Therapeutics, Inc.

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 67.2%

Entrada Therapeutics, Inc. Technicals Summary

Sell

Neutral

Buy

Entrada Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Entrada Therapeutics, Inc. Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.
9.61%
17.97%
52.32%
-34.14%
-20.5%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-19.29%
-22.98%
-6.09%
16.5%
106.01%
Biontech Se
Biontech Se
6.62%
28.33%
24.67%
-65.3%
465.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-12.52%
67.25%
57.65%
33.12%
110.8%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.08%
3.32%
31.85%
151.49%
110.78%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.
13.06
13.06
NA
1.03
0.16
0.07
NA
11.93
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.25
18.25
1.1
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.
Buy
$703.5M
-20.5%
13.06
25.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.1B
106.01%
18.25
33.61%
Biontech Se
Biontech Se
Buy
$27.1B
465.36%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
110.8%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.1B
110.78%
32.84
-4.51%

Entrada Therapeutics, Inc. Institutional Holdings

  • Baker Bros Advisors LP

    13.00%
  • Mpm Asset Management, LLC

    11.83%
  • 5AM Venture Management, LLC

    11.78%
  • T. Rowe Price Associates, Inc.

    8.38%
  • FMR Inc

    4.66%
  • BlackRock Inc

    4.53%

Company Information about Entrada Therapeutics, Inc.

entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.

Organization
Entrada Therapeutics, Inc.
Employees
177
CEO
Mr. Dipal Doshi
Industry
Services

FAQs